Metraipolis › archive › dc_d306d40f68da

Intravitreal Brolucizumab for Diabetic Macular Edema: Outcomes in Treatment-Naive and Anti-VEGF-Switched Eyes over 48 Weeks — Europe PMC PMID:42452622

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42452622
DOI
10.3390/jcm15135162
License (as archived)
solo-consultazione
Archived
2026-10-18T11:50:11.495Z
SHA-256 of the archived text
44165cff38ccbfc023482beefed4e65a6c43d66c2ccf8a09a9621502e97d8d32
Stable URL of this page
https://metraipolis.com/documento/dc_d306d40f68da

How to cite

Intravitreal Brolucizumab for Diabetic Macular Edema: Outcomes in Treatment-Naive and Anti-VEGF-Switched Eyes over 48 Weeks — Europe PMC PMID:42452622 — Europe PMC (en), https://europepmc.org/article/MED/42452622 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d306d40f68da (Metraipolis archive dc_d306d40f68da, sha256 44165cff38ccbfc023482beefed4e65a6c43d66c2ccf8a09a9621502e97d8d32)
BibTeX
@misc{dcd306d40f68da,
  title = {Intravitreal Brolucizumab for Diabetic Macular Edema: Outcomes in Treatment-Naive and Anti-VEGF-Switched Eyes over 48 Weeks — Europe PMC PMID:42452622},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42452622},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d306d40f68da; sha256 44165cff38ccbfc023482beefed4e65a6c43d66c2ccf8a09a9621502e97d8d32},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42452622. Agents can read the archived copy with the MCP tool read_document.